Analysis: India issues first compulsory drugs licence
In one of his final tasks before leaving the job, the outgoing head of India’s patent office has issued the country’s first compulsory licence over a drug since India began protecting pharmaceutical products seven years ago
PH Kurian’s decision to grant domestic generic drug manufacturer Natco a licence to make sorafenib, a cancer-treating drug whose patent is held by Bayer, has been hailed as “groundbreaking” by patient advocates but described as “disappointing” by originator pharmaceutical companies....
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.